Highlights Resverlogix Corp.

Equities

RVX

CA76128M1086

Market Closed - Toronto S.E. Other stock markets 20:49:15 13/05/2024 BST			5-day change	1st Jan Change
0.06 ^CAD	+9.09%		0.00%	-14.29%

04-01	Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-21	Resverlogix Corp. Announces Resignation of Shawn Lu from the Board of Directors	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Resverlogix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Resverlogix Corp. Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes	04/10/23	CI
Resverlogix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
Resverlogix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/11/22	CI
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions	28/09/22	MT
Resverlogix up 4% as Publishes New Data Highlighting Apabetalone's Benefit in Non-alcoholic Fatty Liver Disease	22/08/22	MT
Resverlogix Publishes New Data Highlighting Apabetalone's Benefit in Non-alcoholic Fatty Liver Disease	22/08/22	MT
Resverlogix Brief: Publishing New Data Highlighting Apabetalone's Benefit in Non-alcoholic Fatty Liver Disease	22/08/22	MT
Resverlogix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22	CI
Resverlogix Reports Research Highlighting Safety of BD2-selective BET Inhibitors; Shares Fell 12% on Tuesday	08/06/22	MT
Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
U.S. Food and Drug Administration Grants Resverlogix Corp. Request for Type C Meeting to Review Clinical Trial Protocol for Phase 3 Study	09/05/22	CI
Resverlogix Brief: Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study	09/05/22	MT
Resverlogix Details One-Year Extension of Debenture	19/04/22	MT
Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	31/03/22	CI
Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada	17/02/22	MT
Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada	17/02/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Resverlogix Corp.

Equities

RVX

CA76128M1086

Highlights

Filters